Cognition Therapeutics, Inc.

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 19243B102 since 12/18/2024, largest first.

Filer	% of Class	Shares	Form	Filed
BIOS Memory SPV I, LP 13D/A	6.9%	6,059,555	13D/A	9/23/2025 Event 9/19/2025
Bios Memory SPV I, LP	1.6%	1,424,014
Bios Memory SPV II, LP	0.4%	385,248
Bios Fund I, LP	0.5%	418,926
Bios Fund I QP, LP	0.3%	245,029
BP Directors, LP	<0.1%	32,328
Bios Fund II, LP	0.1%	78,298
Bios Fund II QP, LP	0.3%	255,765
Bios Fund II NT, LP	<0.1%	34,238
Bios Fund III, LP	0.4%	309,748
Bios Fund III QP, LP	2.3%	2,021,906
Bios Fund III NT, LP	0.4%	326,733
Bios Clinical Opportunity Fund, LP	0.6%	500,095
Bios Equity Partners, LP	1.2%	1,081,531
Bios Equity Partners II, LP	0.4%	368,301
Bios Equity Partners III, LP	3.0%	2,658,387
Bios Equity Cof, LP	0.6%	500,095
Cavu Management, LP	6.3%	5,532,233
Bios Capital Management, LP	6.8%	6,032,328
Cavu Advisors, LLC	6.3%	5,532,233
Bios Advisors GP, LLC	6.8%	6,032,328
Leslie W. Kreis	6.3%	5,532,233
Aaron G.L. Fletcher	6.9%	6,059,555
Under 5%, checked the "5 percent or less" box, or amended by a later filing (1)
Pathstone Family Office, LLC 13G	0%	0	13G	2/4/2025 Event 5/23/2024

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q3	15	4.85 M	$4.65 M	$0
2026 Q2	66	22.6 M	$26.0 M	$0
2026 Q1	75	21.4 M	$16.3 M	$0
2025 Q4	80	21.5 M	$29.0 M	$0
2025 Q3	70	21.3 M	$28.7 M	$0
2025 Q2	49	11.2 M	$3.50 M	$0
2025 Q1	52	11.6 M	$4.89 M	$0
2024 Q4	46	11.1 M	$7.78 M	$0
2024 Q3	42	4.25 M	$1.99 M	$0
2024 Q2	48	5.31 M	$8.82 M	$0
2024 Q1	51	7.10 M	$12.9 M	$0
2023 Q4	40	7.18 M	$13.3 M	$0
2023 Q3	37	7.24 M	$10.4 M	$0
2023 Q2	36	7.10 M	$13.0 M	$0
2023 Q1	33	7.14 M	$14.1 M	$0
2022 Q4	38	9.48 M	$10.6 M	$0
2022 Q3	34	7.32 M	$13.9 M	$0
2022 Q2	29	5.19 M	$11.4 M	$0
2022 Q1	29	1.67 M	$4.60 M	$0
2021 Q4	21	1.33 M	$8.44 M	$0